This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
I was very interested in the letter by Griffiths and Sodeify (Arch Dermatol 112:1791, 1976) in which rifampin is mentioned as a valuable drug for the treatment of cutaneous leishmaniasis.I would like to report the case of a 19-year-old woman who had a 4 × 4-cm ulcer of eight months' duration on the right forearm. On October 1976, a Giemsa stain revealed Leishman-Donovan bodies on a smear obtained from the base of the ulcer. The patient was started on a pentavalent antimonial compound, methylglucamine antimoniate (Glucantime [France]; no comparable US product); she received two courses, (ten injections of 1.5 gm each) during a period of four weeks, without any signs of improvement. After reading the above-mentioned letter, I decided to start her on a regimen of rifampin, 600 mg twice a day for ten days; complete healing of the lesion with this treatment was observed. If
Vásquez FR. Rifampin in Leishmaniasis. Arch Dermatol. 1977;113(11):1610-1611. doi:10.1001/archderm.1977.01640110130031